Empagliflozin in ESKD - A Feasibility Study
Sponsor: University of Mississippi Medical Center
This PHASE1/PHASE2 trial investigates Heart Failure and Kidney Failure, Chronic and is currently actively recruiting participants. University of Mississippi Medical Center leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Jul 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2024 — Jul 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 5 earlier versions
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2023 — Feb 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jul 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Feb 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Mississippi Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .